[Intensive hospital monitoring of adverse reactions to benzodiazepines and neuroleptic agents].
BACKGROUND
The main aims of the programme were to highlight the incidence of adverse reactions to the drugs monitored and to define the risk/benefit ratio taking account of the main physiological and physiopathological variations of patients. This paper reports the results of the programme regarding to adverse effects correlated to the use of some psychiatric drugs (benzodiazepines and neuroleptics).


METHODS
A total of 73 records were compiled for 64 patients treated with benzodiazepines and/or neuroleptics.


RESULTS
A very high mean incidence of adverse events was documented (48%) without any severe undesirable effects. 92% of patients treated with neuroleptics reported adverse events. Haloperidol, which caused adverse effects in 80% of patients, revealed mild or moderate forms of parkinsonism (15%), spasm (15%), rigidity (10%), akathisia (5%), reversible postural hypotension (10%), temporary reduction of the visual field (10%), delayed menstrual flow (5%), xerostomia (10%), excessive sweating (10%) and sialorrhea (10%). All the patients treated with clozapine showed adverse effects including postural hypotension (29%), persistent tachycardia (14%), sialorrhea (29%), excessive sweating (14%) and akathisia (14%). Spasms (25%), rigidity (25%) and akathisia (25%) were correlated to the use of clothiapine, whereas postural hypotension was referred to clopenthixol. 44% of patients treated with benzodiazepines showed undesired effects. 20% of those taking chlordemethyldiazepam showed somnolence (33%), sedation (22%) and dysar-thria (44%). Prolonged sedation was observed in 30% of all patients treated with lorazepam. Prazepam was correlated with adverse effects in 75% of cases. No adverse event was documented with bromazepam.


CONCLUSIONS
A higher incidence of adverse events was documented than literature data. Further periods of intensive monitoring will be required to obtain a greater quantity of data from the intensive monitoring of adverse events through the MIO '97 programme.
Mangrella
M
M
Facoltà di Medicina e Chirurgia, Istituto di Farmacologia e Tossicologia, Seconda Università degli Studi, Napoli.
Motola
G
G
Russo
F
F
Mazzeo
F
F
Falcone
G
G
D'Alessio
O
O
Piucci
B
B
Rossi
F
F
D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D008991:Monitoring, Physiologic
D014150:Antipsychotic Agents; D001569:Benzodiazepines
Monitoraggio intensivo ospedaliero delle reazioni avverse da benzodiazepine e neurolettici.